Prof. PeptideProf. Peptide
Guide

How is NAD+ dosed?

Clinics commonly give NAD+ by subcutaneous injection at 20,000–200,000 mcg (20–200 mg) (20–200 mg) one to three times a week, or by intravenous infusion at 100,000–1,000,000 mcg (100–1,000 mg) a session. Every completed human study of injected NAD+ used intravenous infusion. This page reads each study’s molecule, route and dose, keeps NAD+ separate from its precursors NMN and NR, and sets the clinic doses beside them.

Topic: Reading which molecule and which route every NAD+ study actually used, and what clinics give by route

Audience: Anyone comparing an NAD+ dose figure against what was actually studied, in which form and by which route

Reading time: 10–12 minutes

No approved product; every completed study of injected NAD+ was intravenous

NAD+ has not been approved by the FDA; clinics prescribe it compounded, and FDA has it under evaluation for 503A compounding. Every completed, published human study of injected NAD+ used intravenous infusion, a different route from the subcutaneous injection clinics most often prescribe and Prof. Peptide’s NAD+ calculator is scoped to. One trial with a subcutaneous NAD+ arm is recruiting, with no results yet. Every figure on this page is a fact about a specific study or a reported clinic practice, not a recommendation.

What dose do clinics give, and how does it compare?

Clinics commonly prescribe NAD+ by subcutaneous injection at 20,000–200,000 mcg (20–200 mg) one to three times a week; several start at about 20,000 mcg (20 mg) and work up to about 100,000 mcg (100 mg) per injection [8][9][10][11]. By intravenous infusion the range reported is 100,000–1,000,000 mcg (100–1,000 mg) a session, given slowly over 2 to 4 hours [8][12]. Nasal sprays run about 25,000–30,000 mcg (25–30 mg) a spray once a day, and the oral precursors NMN and NR 250,000–500,000 mcg (250–500 mg) a day [8]. Each clinic's own protocol is in the dosing tables on the NAD+ profile.

Clinics explain the different numbers by absorption: injected and infused NAD+ bypass digestion, so they describe a 50,000 mcg (50 mg) injection as no weaker than a 500,000 mcg (500 mg) pill [8][16]. They describe intravenous side effects, chest tightness, flushing and nausea, as rate-dependent, with infusion reactions when NAD+ is given too rapidly, and nasal irritation with the spray [13]. Headache, fatigue and reflux are among the common effects clinics list; they stop treatment for an allergic reaction, chest pain or signs of liver stress, and avoid NAD+ in pregnancy and breastfeeding and in active cancer [13][14][15]. Clinics describe injected NAD+ as a compounded prescription product that is not FDA-approved [14][15].

NAD+, NMN, and NR: one molecule and two precursors

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors the body converts into NAD+ over time, rather than NAD+ itself. Most trials cited in NAD+ discussions, including a landmark study of oral NR in older adults, studied a precursor, not NAD+ directly. The NAD+ profile covers that broader precursor literature, the clinic protocols and the underlying biology in more depth; this page reads the studies of NAD+ itself, states their route, and never presents a precursor’s result as if it were one.

The evidence below comes first, with molecule and route stated for each study, then clinic practice, attributed.

What the studies of NAD+ itself gave, by route

Five studies of NAD+ itself are published or registered: three completed studies of intravenous NAD+, one randomized trial of an oral NAD+ formulation, and one registered intravenous trial with no results. The published ones were re-read at Europe PMC on November 6, 2026.

ChromaDex IV Tolerability Comparison — NAD+ vs. NR vs. Oral NR

NCT06382688

Molecule and route: NAD+ (nicotinamide adenine dinucleotide) and NR (nicotinamide riboside), a direct head-to-head, not a precursor study alone.

UNKNOWN (per the registry's own status field when last read); no results posted. Not re-read on November 6, 2026: the registry's study pages render client-side and its API is closed to crawlers.

Design: Two-part randomized, double-blind study in healthy adults. Study 1 included all four arms (37 participants); Study 2 included only the active NR and NAD+ arms, to further evaluate IV tolerability and comfort.

Arms: 53 participants total (actual, per the registry): 500,000 mcg (500 mg) IV NAD+, 500,000 mcg (500 mg) IV NR, 500,000 mcg (500 mg) oral NR (Study 1 only), or IV placebo (saline).

Endpoint reported: No results had been posted to the registry and no peer-reviewed publication was found for this page.

Topline absent: a registered trial directly comparing IV NAD+ to IV and oral NR, with no reported outcome.

Yu et al. 2026 — NAD+ for Heart Failure (Ischemic Cardiomyopathy)

Yu X, Xu J, Cao J, et al. Am J Cardiovasc Drugs. 2026;26(1):97–106. PMID 40954388. ChiCTR2200059169 (Chinese Clinical Trial Registry).

Molecule and route: NAD+ (nicotinamide adenine dinucleotide) itself, not a precursor, given intravenously.

Completed, peer-reviewed

Design: Single-center, prospective, randomized, placebo-controlled trial in 180 adults with ischemic cardiomyopathy (left ventricular ejection fraction, LVEF, of 45% or less; New York Heart Association, NYHA, class II–III), alongside guideline-directed medical therapy.

Arms: Intravenous NAD+ 10,000 mcg (10 mg) a day, or an equivalent placebo (5% glucose/normal saline), for 7 days.

Endpoint reported: Primary endpoint (LVEF at 1 month): 45.44% (NAD+) versus 42.44% (placebo), p=0.024, statistically significant. Secondary trends (not individually significant): lower NT-proBNP, a blood marker of heart strain, at day 7 (p=0.102), fewer 6-month major adverse cardiac and cerebrovascular events (14.6% vs 24.7%, p=0.089), more NYHA functional-class improvement.

Adverse events reported: The abstract states no adverse-event rate for either arm.

Abstract re-read at Europe PMC on November 6, 2026. Registered with China's trial registry (ChiCTR), not a US NCT number. The only randomized trial of NAD+ itself to measure a clinical outcome found for this page.

Reyna et al. 2026 — Retrospective Real-World Tolerability, NAD+ vs. NR

Reyna K, Heinzen G, Patel N, et al. Front Aging. 2026;7:1652582. PMID 41704678.

Molecule and route: NAD+ (nicotinamide adenine dinucleotide) and NR (nicotinamide riboside), both by IV, a direct comparison.

Completed, peer-reviewed, retrospective (not a randomized trial)

Design: Retrospective review of electronic medical records from a commercial wellness clinic, with 30-day follow-up.

Arms: 14 clients: 6 received IV NAD+ and 8 IV NR, each 500,000 mcg (500 mg) a day for 4 consecutive days.

Endpoint reported: Average infusion time: 97 minutes (NAD+) versus 37 minutes (NR), because symptoms slowed the NAD+ infusions. Liver, kidney, inflammation and thyroid markers were unchanged; HDL cholesterol fell in the NAD+ group.

Adverse events reported: All 6 IV NAD+ clients reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, a faster heart rate, throat pain, congestion and chest pressure during infusion, ending once the infusion finished. 5 of the 8 NR clients reported minor tongue, jaw and arm tingling and minor cramping; one had severe cramping coinciding with menstruation on day 2 and continued treatment.

Full text read at Europe PMC on November 6, 2026. A retrospective chart review from a single commercial clinic, not a randomized controlled trial, a weaker design than Yu et al. 2026.

Grant et al. 2019 — A 6-Hour Intravenous NAD+ Infusion

Grant R, Berg J, Mestayer R, et al. Front Aging Neurosci. 2019;11:257. PMID 31572171.

Molecule and route: NAD+ itself, given intravenously.

Completed, peer-reviewed pilot (not randomized)

Design: Pilot study in 11 healthy men aged 30–55: 8 received NAD+ and 3 a saline control.

Arms: 750,000 mcg (750 mg) NAD+ in normal saline infused over 6 hours (about 2 mg a minute).

Endpoint reported: Plasma NAD+ and its metabolites did not change for the first 2 hours: infused NAD+ was rapidly and completely removed from the plasma. Urinary NAD+ and methylnicotinamide rose at 6 hours.

Adverse events reported: No adverse events were observed during the 6-hour infusion in either group.

Full text read at Europe PMC on November 6, 2026. Small and without randomization; a pharmacokinetic study, not an outcome trial.

Kornilov et al. 2026 — An Oral NAD+ Formulation (RENEWAL-NAD+)

NCT07336836

Kornilov SA, et al. Geroscience. 2026. PMID 42530810.

Molecule and route: NAD+ itself, as a modified oral formulation (LathMized NAD+, LNAD+), not a precursor.

Completed, peer-reviewed; registered retrospectively (January 4, 2026)

Design: Double-blind, randomized, placebo-controlled phase 0/1b trial in healthy adults aged 45–75 (60 randomized; primary analysis 50).

Arms: Oral LNAD+ or placebo for 5 days; the abstract gives no milligram figure.

Endpoint reported: NAD inside blood cells rose 53% against placebo by day 6; plasma NAD did not change (p=0.60); NAD breakdown products rose sharply.

Adverse events reported: Symptom incidence was comparable between groups (p=0.68); one mild adverse event (grade 1 nausea) occurred in the LNAD+ arm.

Abstract read at Europe PMC on November 6, 2026. Several authors list an affiliation with Bryleos. An oral study: its results do not transfer to injections.

The studies beside clinic doses

Set beside the studies, the clinic intravenous range sits far above the 10,000 mcg (10 mg) a day of the heart-failure trial, the only one to measure a clinical benefit [2]. The two studies at clinic-level doses, 500,000 mcg (500 mg) a day for 4 days in a clinic chart review [3] and 750,000 mcg (750 mg) over 6 hours in a pilot [4], measured tolerability, not benefit; in the review, symptoms stretched NAD+ infusions to an average of 97 minutes. No source was found deriving the clinic figures from any trial.

The subcutaneous gap: one recruiting trial, no completed one

No completed human trial of subcutaneous NAD+ has been published, although it is the route clinics most often prescribe. One registered trial tests it directly:

Absorption and Tolerability of Injectable Niagen®+ vs. NAD+ (Includes a Subcutaneous NAD+ Arm)

NCT06919328

RECRUITING when last read; no results posted. Not re-read on November 6, 2026 (the registry's study pages render client-side and its API is closed to crawlers).

Design: Randomized study in healthy adults evaluating subjective effects and tolerability of NR and NAD+ across three injection routes.

Arms: 70 participants planned (estimated), across nine arms: NR by intramuscular injection, NR by subcutaneous injection, NR by IV push, NAD+ by intramuscular injection, NAD+ by subcutaneous injection, NAD+ by IV push, and three matching bacteriostatic-water placebo arms, each active arm dosed at 100,000 mcg (100 mg) in 2 mL bacteriostatic water.

This is the one trial found that tests the route Prof. Peptide's own NAD+ calculator is scoped to (subcutaneous). It is recruiting, with no posted results, so it is reported here as the closest match to the calculator's scope, not as completed evidence.

The NAD+ reconstitution calculator and the peptide dosage calculator work out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. Neither sets a dose.

Regulatory position: under FDA evaluation for compounding, and NMN’s separate history

NAD+ is in Category 1, under evaluation, of FDA’s 503A nominations list, and is not on its safety-risk list.

FDA's list of bulk drug substances nominated for 503A compounding, updated May 14, 2026, places Nicotinamide Adenine Dinucleotide (NAD) in Category 1, bulk drug substances under evaluation; a separately nominated Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate is in Category 3, nominated without adequate support [7]. NAD+ does not appear on FDA's page of bulk drug substances that may present significant safety risks, where BPC-157, TB-500, ipamorelin and CJC-1295 are named [6]. It is not an FDA-approved drug, and clinics prescribe it as a compounded medication [14].

NMN, a precursor and not NAD+ itself, has its own separate regulatory history: FDA excluded it from the dietary-supplement definition in fall 2022, applying the drug-preclusion clause on the grounds that NMN had first been authorized for investigation as a new drug. In a citizen-petition response dated September 29, 2025, FDA concluded that NMN is not excluded from the definition, finding that NMN was marketed as a dietary supplement in the US as early as 2017. FDA still treats NMN as a new dietary ingredient subject to premarket notification, and says an acknowledgement of a notification is not a finding that a product is safe. That history concerns NMN’s status as a supplement ingredient, not NAD+’s compounding status, and this page keeps the two distinct.

FAQ

Is there an FDA-approved NAD+ product?
No. NAD+ has not been approved by the FDA as a drug for any indication. Clinics prescribe it as a compounded drug, by subcutaneous injection, intravenous infusion or nasal spray, and FDA lists Nicotinamide Adenine Dinucleotide (NAD) in Category 1, under evaluation, of its 503A compounding nominations list. Research-grade vials are sold for laboratory use only.
Do NAD+ trials use the same route Prof. Peptide's calculator covers?
No completed one does. Every completed human study of injected NAD+ found for this page used intravenous infusion, and the one randomized trial of a swallowed NAD+ formulation was oral. Prof. Peptide's NAD+ reconstitution calculator is scoped to subcutaneous dosing, where clinics give 20,000–200,000 mcg (20–200 mg) per injection, against 100,000–1,000,000 mcg (100–1,000 mg) per intravenous session. One recruiting trial, NCT06919328, includes a subcutaneous NAD+ arm (100,000 mcg, 100 mg), with no results posted.
What dose did the NAD+ heart failure trial use?
Yu et al. 2026 (PMID 40954388) gave intravenous NAD+ at 10,000 mcg (10 mg) a day for 7 days to 180 adults with heart failure from ischemic cardiomyopathy, registered with the Chinese Clinical Trial Registry (ChiCTR2200059169), not a US ClinicalTrials.gov NCT number. At 1 month, the NAD+ group showed a significantly greater improvement in left ventricular ejection fraction than placebo (45.44% vs. 42.44%, p=0.024).
What adverse events were reported for IV NAD+?
Reyna et al. 2026 (PMID 41704678), a retrospective review of a commercial clinic's records, reported that all 6 clients receiving IV NAD+ (500,000 mcg (500 mg) a day for 4 days) had moderate to severe gastrointestinal symptoms, a faster heart rate and chest pressure during infusion, which ended when each infusion finished. In a 6-hour, 750,000 mcg (750 mg) infusion in 8 men, no adverse events were observed (Grant et al. 2019). Clinics describe intravenous side effects (chest tightness, flushing, nausea) as rate-dependent.
Are NMN and NR the same thing as NAD+?
No. NAD+ is the molecule itself. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors: the body converts them into NAD+ over time rather than receiving NAD+ directly. Several trials commonly cited in NAD+ discussions, including the landmark NR trial in older adults, studied a precursor, not NAD+ itself. This page states which molecule each cited study used and does not present a precursor's result as an NAD+ result.
How does the studied dose compare to what clinics give?
Clinics give 100,000–1,000,000 mcg (100–1,000 mg) per intravenous session, as cited on the NAD+ profile. The heart-failure trial gave 10,000 mcg (10 mg) a day for 7 days; the clinic chart review gave 500,000 mcg (500 mg) a day for 4 days; and the infusion pilot gave 750,000 mcg (750 mg) over 6 hours. So the trial that measured a clinical benefit used a dose far below clinic practice, and the studies at clinic-level doses measured tolerability, not benefit.
What is NAD+'s FDA compounding status?
FDA's 503A bulk drug substances nominations list (updated May 14, 2026) places Nicotinamide Adenine Dinucleotide (NAD) in Category 1, bulk drug substances under evaluation; a separately nominated Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate is in Category 3, nominated without adequate support. NAD+ does not appear on FDA's page of bulk substances that may present significant safety risks. Separately, NMN (a precursor) has its own FDA history as a dietary-supplement ingredient: excluded from the definition in fall 2022, then found not excluded in a citizen-petition response dated September 29, 2025, while still subject to new-dietary-ingredient notification.

References

  1. ClinicalTrials.gov. IV Administration of ChromaDex's Niagen® as Compared to NAD+, NCT06382688. Not re-read November 6, 2026 (client-rendered page). https://clinicaltrials.gov/study/NCT06382688
  2. Yu X, Xu J, Cao J, et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs. 2026;26(1):97–106. PMID 40954388. ChiCTR2200059169. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/40954388/
  3. Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PMID 41704678. Full text read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/41704678/
  4. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019;11:257. PMID 31572171. Full text read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/31572171/
  5. ClinicalTrials.gov. Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+, NCT06919328. Not re-read November 6, 2026 (client-rendered page). https://clinicaltrials.gov/study/NCT06919328
  6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026; read November 6, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  7. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3). Updated May 14, 2026; read November 6, 2026. https://www.fda.gov/media/94155/download
  8. Pru. How much NAD+ should you take per day? Blog, updated July 9, 2026; read November 6, 2026. Cited for its own dose ranges by route and its explanation of why they differ. https://joinpru.com/blog/nad-dosage
  9. Empower Pharmacy, a compounding pharmacy. NAD+ Injection (Aqueous). Read November 6, 2026. Cited for its own subcutaneous protocol (about 20 mg to start, up to about 100 mg per injection, 1 to 3 times weekly). https://www.empowerpharmacy.com/compounding-pharmacy/nad-injection-aqueous/
  10. Invigor Medical. NAD+ FAQ's. Read November 6, 2026. Cited for its own protocol (up to 50 units, 100 mg, of a 1,000 mg in 5 mL vial, 1 to 3 times per week). https://help.invigormedical.com/en/articles/7016924-nad-faq-s
  11. Superpower. NAD+ Injections: informed medical consent. Read November 6, 2026. Cited for its own protocol (20 mg, rising 20 mg a week to 100 mg, 1 to 3 times per week; not over 300 mg a week). https://superpower.com/informed-medical-consent/nad-injections
  12. Peach IV. NAD+ dosage and frequency guide. Read November 6, 2026. Cited for its own intravenous range (about 100 mg up to 1,000 mg a session, over 2 to 4 hours). https://www.peachiv.com/blog-post/nad-dosage-frequency-guide
  13. Marek Health. NAD+ (treatment page). Read November 6, 2026. Cited for its route-specific side effects, serious risks and the cases it lists as not appropriate. https://marekhealth.com/treatments/nad-plus
  14. Ivim Health. Important NAD+ safety information. Read November 6, 2026. Cited for its common and serious side effects, who should avoid NAD+, and its compounding statement. https://www.ivimhealth.com/important-nad-nicotinamide-adenine-dinucleotide-safety-information/
  15. Hone Health. NAD+ injections. Article updated May 27, 2026, medically reviewed by Natalie Kunsman, M.D.; read November 6, 2026. Cited for its prescription and pregnancy statements. https://honehealth.com/edge/nad-injections/
  16. Defy Medical. What is an NAD+ shot? Blog; read November 6, 2026. Cited for its statement that injected NAD+ is not lost to digestion. https://www.defymedical.com/blog/what-is-nad-shot/
  17. Kornilov SA, et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. Geroscience. 2026. PMID 42530810. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/42530810/
  18. U.S. Food and Drug Administration. Response to new dietary ingredient notification 1259 (NMN), concluding NMN is excluded from the dietary supplement definition. October 11, 2022. Docket document FDA-2022-S-0023-0051. https://www.regulations.gov/document/FDA-2022-S-0023-0051
  19. U.S. Food and Drug Administration. Response to citizen petition FDA-2023-P-0872 on NMN and the dietary supplement definition (granted in part, denied in part). September 29, 2025. Docket document FDA-2023-P-0872-2754. https://www.regulations.gov/document/FDA-2023-P-0872-2754

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated